Myriad Genetics, Inc.

MYGN

$3.23

+0.00%

N/A+$0.00

Healthcare

Medical - Diagnostics & Research

NASDAQ

Active Trading

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s ...

Recent News of MYGN

Seeking Alpha7/31/2026Neutral

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Zacks Investment Research7/30/2026Neutral

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.05 per share a year ago.

GlobeNewsWire7/30/2026Neutral

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cycle initiatives expected to improve reimbursement predictability and performance.

GlobeNewsWire7/23/2026Neutral

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. The company's quarterly earnings will be released the same day after the market closes.

GlobeNewsWire7/21/2026Neutral

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks

Myriad Genetics, Inc.

Recent News of MYGN

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Is This the Right Time to Hold MYGN Stock in Your Portfolio?

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer

Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Should You Add Myriad Genetics Stock to Your Portfolio Right Now?

Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock

Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh

MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Supply Chain of MYGN

Upstream

Downstream

Proxies

Recent News of MYGN

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Is This the Right Time to Hold MYGN Stock in Your Portfolio?

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer

Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Should You Add Myriad Genetics Stock to Your Portfolio Right Now?

Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock

Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh

MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Supply Chain of MYGN

Upstream

Downstream

Proxies